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The cytokine macrophage migration inhibitory factor (MIF) is a constitutive element of the host antimicrobial
defenses and stress response that promotes proinflammatory function of the innate and acquired immune
systems. MIF plays an important role in the pathogenesis of acute and chronic inflammatory or autoimmune
disorders, such as sepsis, acute respiratory distress syndrome, asthma, rheumatoid arthritis, and inflammatory
bowel diseases. Polymorphisms of the human MIF gene (that is, guanine-to-cytosine transition at position
173 or CATT-tetranucleotide repeat at position 794) have been associated with increased susceptibility to
or severity of juvenile idiopathic and adult rheumatoid arthritis, ulcerative colitis, atopy, or sarcoidosis.
Whether these MIF polymorphisms affect the susceptibility to and outcome of sepsis has not yet been examined.
Analyses of MIF genotypes in patients with sepsis may help to classify patients into risk categories and to
identify those patients who may benefit from anti-MIF therapeutic strategies.
The innate immune system assumes an essential role
in the natural host defenses against microbes [1, 2].
Sensing of microbial pathogens, either in tissue in con-
tact with the host’s environment or in the systemic
circulation after invasion of the bloodstream, is car-
ried out by macrophages, dendritic cells, natural killer
cells, granulocytes, and monocytes acting as sentinels
of the innate immune system. Binding of microbial
products to pathogen recognition molecules activates
signal-transduction pathways and the transcription of
immune genes, resulting in the expression of costim-
ulatory molecules at the cell surface and in the release
of immunoregulatory effector molecules in the extra-
cellular compartment [1, 3].
Failure to recognize pathogens at an early stage of
invasion, for example because of genetic defects in the
ability of macrophages to detect and kill microbial path-
ogens, facilitates unrestricted microbial growth and the
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development of overwhelming and potentially life-
threatening infections [4, 5]. Among numerous effector
molecules involved in the antimicrobial host defenses,
cytokines have a crucial role because they kick off the
host inflammatory response and coordinate the cellular
and humoral responses aimed at the eradication or the
containment of invasive pathogens [6]. The increased
susceptibility to infection of transgenic animals with
qualitative or quantitative defects of their cytokine re-
sponse, due to mutations or deletions of cytokine or
cytokine receptor genes, is an example of the critical
role played by cytokines or cytokine receptors in an-
timicrobial host defenses [6]. However, exuberant pro-
duction of proinflammatory mediators may also be-
come life-threatening, as observed in patients with
severe sepsis or septic shock [7–9], indicating that a
tight control of cytokine production is essential for bal-
anced innate immune responses.
MACROPHAGE MIGRATION INHIBITORY
FACTOR
Investigations of the delayed-type hypersensitivity re-
action conducted 40 years ago led to the identification
of one of the first cytokine activities: macrophage mi-
gration inhibitory factor (MIF). It was described orig-
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Figure 1. Mode of action of macrophage migration inhibitory factor (MIF). MIF may exert its biological effects either via the binding to a cognate
receptor (1) or via a nonclassical endocytic pathway (2). MIF is associated with activation of the extracellular signal–regulated kinase-1/2 (ERK-1/2),
promoting cell growth and activating Ets transcription factors (3) shown to be critical for the expression of the Toll-like receptor 4 (TLR4) gene (Tlr4)
encoding for the signal-transducing molecule of the endotoxin receptor complex. By up-regulating TLR4 expression, MIF facilitates the sensing of
endotoxin-containing particles (4), thereby promoting the production of proinflammatory mediators, including cytokines (such as MIF) and nitric oxide
(NO) (5). MIF activates a series of events initiated by the phosphorylation of ERK-1/2 and followed by the production of cytoplasmic phospholipase
A2 (cPLA2), arachidonic acid, and prostaglandin E2 (PGE2) (6). Via the generation of oxidoreductase activity, NO and cyclooxygenase (COX)–2, MIF
prevents activation-induced apoptosis mediated by the oxidative burst (7) and by p53 (8). Finally, MIF counterbalances the immunosuppressive effects
of glucocorticoids (9). GR, glucocorticoid receptor; iNOS, inducible nitric oxide synthase; MMPs, matrix metalloproteinases; NF-kB, nuclear factor–kB.
Adapted from Calandra et al. [14].
inally as a factor released by activated lymphocytes that inhib-
ited the random migration of exudate cells, hence its name [10,
11]. Until the cloning of a human MIF complementary DNA
in 1989 [12] and its rediscovery in 1991 as a pituitary-derived
peptide released after exposure to endotoxin [13], MIF had
remained a mysterious cytokine. The intriguing observation
that MIF was a neuroendocrine mediator potentiating host
responses to microbial products (endotoxin) suggested that
MIF was at the crossroads of the endocrine and immune sys-
tems. It also helped to uncover an important feature of this
molecule, namely its capacity to promote proinflammatory im-
mune functions. Over the past decade, several studies have
revealed that MIF is a regulator of inflammatory and innate
immune responses (reviewed in [14]).
MIF is constitutively expressed by a broad variety of cells
and tissues, including such innate immune cells as monocytes
and macrophages [15], and is rapidly released after exposure
to microbial products (cell wall components and toxins) and
proinflammatory mediators and in response to stress [16–18].
Once released in the extracellular milieu, MIF promotes proin-
flammatory biological activities, acting in an autocrine, para-
crine, or endocrine manner as a regulator of immune responses.
MIF has been shown to counterregulate the immunosuppres-
sive effects of glucocorticoids on immune cells [17], to activate
the extracellular signal–regulated kinase–1/2 (ERK-1/2) mito-
gen-activated protein kinase pathway [19], to inhibit the activity
of JAB-1/CSN5, a coactivator of the activator protein–1 (AP-
1) [20], to up-regulate the expression of Toll-like receptor 4,
to facilitate the sensing of endotoxin-bearing bacteria [21], and
to sustain proinflammatory function of macrophages by in-
hibiting p53-dependent apoptosis [22] (figure 1). As a proin-
flammatory mediator, MIF has been shown to be implicated
in the pathogenesis of severe sepsis and septic shock [13, 16,
17, 23, 24], acute respiratory distress syndrome [25], and several
other inflammatory and autoimmune diseases [26], including
rheumatoid arthritis [27, 28], glomerulonephritis [29, 30], and
inflammatory bowel diseases [31].
A single MIF gene located on chromosome 22q11.2 has been
identified in the human genome [32, 33]. This region is in
syntenic conservation with a region of mouse chromosome 10
containing the mouse Mif gene [34, 35]. The human MIF gene
is short, composed of 3 exons of 205, 173, and 183 bp and 2
introns of 189 and 95 bp (figure 2) [12, 32, 34–38]. Genes with
a high degree of homology with human and mouse Mif have
been identified in the genome of several other mammals (rats,
gerbils, cattle, and pigs), where they are expressed as a single
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Figure 2. Structure of the human macrophage migration inhibitory factor (MIF) gene. The 3 exons, 2 introns, and putative transcription factor–
binding sites are represented by black, white, and gray boxes, respectively. Arrows indicate the positions of the 3 single-nucleotide polymorphisms
and of the CATT(5–8)-tetranucleotide microsatellite. AP, activator protein; CREB, cyclic adenosine 3′,5′-monophosphate–responsive element–bindingprotein;
Ets, E–twenty-six; NF-kB, nuclear factor–kB; Sp1, specificity protein 1.
copy per haploid genome. In contrast to other mammalian
genomes, the mouse genome also contains several processed
(intronless) pseudogenes [34, 35, 38]. Homologues of the hu-
man MIF gene, encoding for proteins sharing ∼30% identity
with MIF at the amino acid level, have been identified in chick-
ens, jawless and jawed fish, ticks, parasites, plants, and cyano-
bacteria [36, 39–42]. The high degree of conservation of the
MIF protein across different animal species suggests that it may
exert important biological functions.
The promoter region of the MIF gene contains several pu-
tative DNA-binding sequences for transcription factors, in-
cluding AP-1, nuclear factor (NF)–kB, Ets, GATA, specificity
protein 1, and cyclic adenosine 3′,5′-monophosphate (cAMP)–
responsive element-binding protein (figure 2). Whether these
DNA-binding sequences are implicated in the control of the
expression of the human MIF gene is not known. Of note,
however, a cAMP-responsive element DNA-binding site located
in the proximal promoter region of the mouse Mif gene, which
is conserved in the human MIF gene promoter, has been im-
plicated in Mif gene activation of AtT-20 mouse pituitary cells
induced by forskolin, an activator of the cAMP-dependent pro-
tein kinase A pathway [43]. To improve our understanding of
the factors implicated in the regulation of the expression of the
MIF gene, it remains imperative to identify which regions of
the MIF promoter and their cognate transcription factors are
implicated in the control of the basal and stimulus-induced
expression of the MIF gene. The MIF 5′ flanking region lacks
a TATA box but is rich in GC nucleotides, 2 characteristics
usually associated with the presence of multiple transcriptional
start sites. Yet, on the basis of primer extension and 5′-rapid
amplification of complementary ends PCR analyses of the hu-
man MIF gene, there is a single RNA initiation start site located
97 bp upstream of the methionine codon [32]. In agreement
with this finding, a single transcriptional start site was also
identified in the mouse Mif gene. A single MIF mRNA species
of ∼800 bp was observed in human, mouse, or rat cell lines or
tissues. The 345-bp open-reading frame of MIF mRNA encodes
for a 115–amino acid nonglycosylated protein of 12.5 kDa.
Crystallographic studies of the human and rat proteins have
revealed that MIF is a homotrimer [44, 45].
MIF GENE POLYMORPHISMS
AND SUSCEPTIBILITY TO INFLAMMATORY
DISEASES
Genetic studies of twins and adoptees have revealed that host
factors are essential determinants of susceptibility to infectious
and autoimmune diseases [46]. Immunogenetic analyses have
linked genes of the major histocompatibility complex (MHC),
as well as non-MHC genes, to increased susceptibility or resis-
tance to several infectious diseases, such as malaria, tuberculosis,
leprosy, AIDS, and viral hepatitis [47]. Of the non-MHC genes,
polymorphisms within the promoter region of cytokines (e.g.,
TNF, IL-1, IL-4, and IL-10) and of cytokine or chemokine re-
ceptors (e.g., IL-7R, IFN-gR, IL-12R, and CCR5) have been as-
sociated with mostly enhanced, but sometimes also reduced
(CCR5), predisposition to inflammatory and infectious diseases.
In recent years, the advent of modern sequencing tools and
the development of high-throughput technologies has greatly
facilitated the study of gene polymorphisms and their impact
on the pathogenesis of human diseases. Susceptibility to infec-
tion and propensity to develop severe inflammatory and im-
mune diseases are likely to be strongly influenced by genetic
factors. By analogy with other cytokines and given the role of
MIF in the control of inflammation and innate immune re-
sponses to microbial invasion, it was reasonable to postulate
that mutations in the human MIF gene would predispose af-
fected hosts to altered susceptibility to or severity of inflam-
matory or infectious diseases. Indeed, loss-of-function MIF
mutations may affect the capacity of the host to mount in-
flammatory and innate immune responses. Alternatively, gain-
of-function MIF mutations may predispose the host to more-
severe inflammatory and immune reactions. Over the last 3
years, a rapidly growing body of literature has linked MIF gene
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Table 1. Allele frequencies of macrophage migration inhibitory
factor (MIF) promoter polymorphisms, CATT(5–8) and 173*G/C, in







No. of CATT repeats 173 SNP
5 6 7 8 G C
[57] UK 342 25.3 65.6 8.8 0.3 88 12
[56] Germany 390 ND ND ND ND 79 21
[51] Spain 122 ND ND ND ND 85 15
[50] US 159 27.7 60.7 11 0.6 ND ND
[54] Japan 750 ND ND ND ND 80.7 19.3
[55] Japan 155 39.4 42.6 17.4 0.6 77.7 22.3
NOTE. ND, not determined; SNP, single-nucleotide polymorphism.
a UK, United Kingdom; US, United States.
b The frequencies of the +254*T, +254*C, +656*C, and +656*G alleles
have been determined only in white subjects in the United Kingdom and were
88.8%, 11.2%, 86.3%, and 13.7%, respectively [49].
polymorphisms with susceptibility to or severity of inflam-
matory diseases in which increased MIF concentrations had
been associated with severe clinical manifestations, high severity
scores, and often poor outcome.
MIF gene polymorphisms. Four polymorphisms of the hu-
man MIF gene have been reported thus far (figure 2): a 5–8-
CATT tetranucleotide repeat at position794 (794 CATT(5–8))
and 3 single-nucleotide polymorphisms (SNPs) at positions
173 (173*G/C), +254 (+254*T/C), and +656 (+656*C/G)
[48–50]. The +254 and +656 SNPs are positioned in introns
and, thus, do not affect the coding sequence of the MIF gene.
MIF genotyping studies have focused on the 794 CATT(5–8)
microsatellite and the 173*G/C polymorphisms but have not
examined the impact of the other 2 known polymorphisms
[48–56]. Table 1 shows a summary of the allele frequencies of
these 2 polymorphisms in cohorts of healthy persons from
different countries. In white subjects from the United Kingdom
or United States and in Japanese, the frequency of the CATT
alleles followed the same ranking order: CATT6, followed by
CATT5, CATT7, and CATT8 [49, 50, 55]. The CATT8 allele was
rare (!1%) in all ethnic groups examined. The CATT6 allele
was predominant in white subjects from the United Kingdom
and United States, whereas the CATT5 and CATT7 alleles were
more frequent in Japanese subjects. In all populations studied,
the 173*G allele (75%–90%) was far more common than the
173*C allele (15%–20%). Of note, in the 2 studies from Japan,
the frequency of the 173*C allele (19.3% and 22.3%) was
almost twice as high as that among the white population from
the United Kingdom (12%). Surprisingly, the 173*C allele
frequency among the German population studied was similar
to that among the Japanese subjects [54–56]. Unfortunately,
the ethnic background of the German population was not re-
ported. Evidence for strong linkage disequilibrium between the
4 polymorphisms was reported in a cohort of 342 white subjects
from the United Kingdom. The CATT5/173*C allele was ex-
tremely rare (1.3%), whereas the CATT7/173*G allele was not
observed.
Arthritis. Previous studies have revealed a role for MIF in
the pathogenesis of rheumatoid arthritis (reviewed in [27, 28]).
Increased MIF levels have been detected in the serum and syn-
ovial fluids of children with juvenile idiopathic arthritis (also
called juvenile rheumatoid arthritis) and of adults with rheu-
matoid arthritis [58, 59]. Immunoneutralization of MIF was
observed to inhibit the development of adjuvant- or collagen-
induced arthritis in experimental animal models [60–62]. It
was therefore not surprising that MIF genotyping studies have
been conducted in cohorts of patients with arthritis with the
aim to look for possible associations between MIF gene poly-
morphisms and susceptibility to or severity of inflammatory
arthritis (table 2).
The 173*G/C SNP was the first MIF gene polymorphism
identified in 2001 by Donn et al. [48], who screened for mu-
tations within 1 kb of the 5′ flanking region of the human MIF
gene in 32 unrelated healthy white subjects in the United King-
dom. Compared with expression of the 173*C allele among
172 healthy subjects, the frequency was increased 2-fold (20.5%
vs. 10.2%) in a cohort of 117 patients with systemic-onset
juvenile idiopathic arthritis. Similar results were obtained when
526 patients with juvenile idiopathic arthritis were compared
with 259 healthy white subjects in the United Kingdom [49],
suggesting that the 173*C allele is likely to confer suscepti-
bility to juvenile idiopathic arthritis. Interestingly, patients with
the173*C allele had increased levels of MIF in the circulation
or in synovial fluids (patients with juvenile idiopathic arthritis)
[49, 63]. Moreover, the presence of a 173*C allele in patients
with juvenile idiopathic arthritis was predictive of a shorter
duration of clinical response to corticosteroid therapy [63]. To
begin to study the molecular mechanism by which the173*C
SNP may affect MIF gene expression, a 775 to +84 region
of the MIF gene (excluding the CATT repeat region) was cloned
in a luciferase reporter vector and tested for promoter activity
in CEMC7A human T lymphoblasts and A549 human lung
epithelial cells [49]. Although the 173*C promoter was more
active than the 173*G promoter in CEMC7A cells, the op-
posite results were obtained in A549 cells, suggesting that the
173 SNP may affect promoter activity in a cell type–specific
manner. On the basis of sequence analysis, it was proposed
that the presence of a cytosine at position173 creates a bind-
ing site for the transcription factor AP4. However, binding of
AP4 to that potential site has not yet been demonstrated.
In 2002, Baugh et al. [50] reported the association between
the 794 CATT(5–8) microsatellite and disease severity in pa-
tients with rheumatoid arthritis. The study included 159 healthy
white subjects in the United States and 184 patients from Wich-
ita, Kansas, with either mild (105 patients) or severe (79 pa-
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Table 2. Association between macrophage migration inhibitory factor gene (MIF) polymorphisms and inflammatory diseases.
Reference Type of disease Countrya Relationship between MIF polymorphisms and disease
[48] Systemic-onset juvenile idiopathic arthritis UK 173*C allele increased susceptibility
[49] Juvenile idiopathic arthritis UK 173*C allele increased susceptibility
[50] Rheumatoid arthritis US CATT5 allele reduced disease severity
[56] Rheumatoid arthritis and juvenile rheumatoid
arthritis
Germany CATT5 allele increased susceptibility to juvenile rheu-
matoid arthritis
173*C allele reduced susceptibility to rheumatoid
arthritis
[52] Inflammatory polyarthritis UK CATT7/173*C haplotype increased susceptibility
[51] Sarcoidosis in erythema nodosum Spain 173*C allele increased susceptibility
[55] Atopy Japan CATT7/173*C haplotype increased susceptibility
CATT5/173*G haplotype reduced susceptibility
[54] Ulcerative colitis Japan 173*C/C genotype increased disease severity
a UK, United Kingdom; US, United States.
tients) rheumatoid arthritis. The CATT5 allele was associated
with a lower disease severity, because it was present in 50% of
the control subjects and 39% and 32% of patients with mild
or severe rheumatoid arthritis, respectively. Using luciferase
reporter assays in COS-7 monkey kidney fibroblasts, the au-
thors showed that the CATT5 promoter construct exhibited
reduced basal and serum or forskolin-stimulated transcriptional
activity, compared with that of any of the CATT6, CATT7, or
CATT8 promoter constructs. The effect of the 173*G/C poly-
morphism was not studied. Recently, the combined effects of
the 794 CATT and the 173 polymorphisms were assessed
in a cohort of 343 white subjects in the United Kingdom and
438 patients with inflammatory polyarthritis [52]. The173*C
allele, the CATT7 allele, and the CATT7/173*C haplotype were
associated with a 1.5-, 1.7-, and 3.0-fold increased risk, re-
spectively, of developing inflammatory polyarthritis (Pp .0001,
, and , respectively), strongly suggesting thePp .02 Pp .0001
presence of a linkage disequilibrium between the 173*C and
CATT7 alleles. In contrast to what had been observed in the
cohort of patients with rheumatoid arthritis in the United States
[50], MIF polymorphisms were surprisingly not associated with
disease severity in the UK population.
Arthritis is a complex and polygenic chronic systemic in-
flammatory disease. To investigate possible associations be-
tween candidate genes and adult or juvenile rheumatoid ar-
thritis, Miterski et al. [56] analyzed the polymorphisms of 13
genes, including MIF, in ∼400 German patients and 300–400
control subjects. None of the candidate genes investigated
(among which were HLA-DRBI, TNF, TNFRI, and TNFRII)
was found to be associated with adult or juvenile rheumatoid
arthritis. Of note, the CATT5 and 173*G alleles were unex-
pectedly significantly more frequent in patients with either adult
or juvenile rheumatoid arthritis than in control subjects. Un-
fortunately, the ethnic background of the case-patients and
control subjects was not reported. Given the critical importance
of control subjects in such studies, it is impossible to draw firm
conclusions from the apparently conflicting results of this study.
One approach to avoid that problem is to perform family-based
analyses. In an elegant study, Donn et al. [53] investigated the
transmission of MIF promoter polymorphisms in 321 white
families in the United Kingdom with one child with juvenile
idiopathic arthritis. The CATT7/173*C haplotype was ob-
served to be transmitted in excess in the patients with juvenile
idiopathic arthritis. Moreover, both conditional and pairwise
extended transmission disequilibrium tests predicted functional
interaction between the 2 polymorphisms. Functional studies
comparing the activities of all possible combinations of the
various CATT and 173 alleles suggested the existence of an
association between the length of the CATT repeat and either
the 173*C allele (CEMC7A T cells) or the 173*G allele
(A549 epithelial cells) in a cell type–dependent manner. How-
ever, in both cell lines, CATT7/173*C promoter activity was
similar to that of CATT5/173*G and CATT6/173*G pro-
moters, a finding in apparent contradiction with the hypothesis
that CATT7 and 173*C alleles enhance promoter activity.
Other inflammatory diseases. Three case-control studies
conducted in other patient populations confirmed and ex-
tended the observations made in patients with arthritis. In the
first study performed in Spain, the frequency of the 173*C
allele was significantly higher in 28 patients with erythema no-
dosum secondary to sarcoidosis (34%) than in 70 patients with
erythema nodosum due to other causes (12%) or in 122 matched
control subjects (15%) [51]. Moreover, the presence of the
173*C allele was found to increase the risk of developing
sarcoidosis in erythema nodosum patients. In the second study,
MIF genotyping was performed in 221 patients with ulcerative
colitis and in 438 healthy control subjects from Japan [54].
There was no difference in the distribution of the 173 ge-
notypes between control subjects and patients with ulcerative
colitis. Yet, there was an overrepresentation of the 173 C/C
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genotypes in the subgroup of patients with severe pancolitis
(i.e., extending to the cecum) (OR, 10.7; 95% CI, 1.3–86.6; P
p .007), suggesting a possible relationship between the173*G/
C polymorphism and disease severity in Japanese patients with
ulcerative colitis. The third case-control study conducted in
Japanese patients with atopy and asthma (349 subjects with
atopy, 197 of whom had asthma, and 235 subjects without
atopy, of whom 80 had asthma) confirmed the existence of
association between the CATT and 173 promoter polymor-
phisms in atopic but not in patients with asthma [55]. Indeed,
the risk of atopy was reduced in carriers of the CATT5/173*G
haplotype, whereas it was increased in carriers of the CATT7/
173*C haplotype. However, analyses of MIF promoter activity
in A549 lung epithelial cells yielded conflicting results, as the
CATT7/173*C promoter exhibited lower activity than the
CATT5/173*G or the CATT6/173*G promoters. These and
other results reported above argue in favor of a complex reg-
ulation of the transcriptional activity and expression of the MIF
gene. Given the lack of information on the identity of proteins
potentially interacting with the CATT and 173 regions of the
MIF promoter, the mechanisms by which these polymorphic
sites may modulate MIF transcription remain unknown.
MIF polymorphisms and sepsis. The studies described
above strongly suggest that MIF gene polymorphisms predis-
pose to the development of inflammatory diseases. Given that
MIF is an important mediator of innate immunity and sepsis
(reviewed in [14]), we postulate that genetic variations within
the MIF gene also may influence predisposition to or outcome
of sepsis. To verify this hypothesis, we are currently investigat-
ing whether the 794 CATT(5–8) and 173*G/C MIF polymor-
phisms play a role in the pathogenesis of human sepsis.
CONCLUSIONS
In recent years, a rapidly growing amount of literature has
revealed an important role for MIF in innate immunity, in-
flammation, and sepsis. Increased systemic or local MIF con-
centrations have been associated with severe clinical manifes-
tations, high severity scores, and often poor outcome of sepsis
and inflammatory and autoimmune diseases. Similarly, poly-
morphisms of the MIF gene have been linked to susceptibility
to or severity of chronic systemic inflammatory diseases. Given
these observations, one would predict that polymorphisms of
the human MIF gene would also predispose affected hosts to
altered susceptibility to or outcome of sepsis. Work is in pro-
gress to verify these assumptions in a cohort of patients with
severe sepsis and septic shock.
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